While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this ...

After decades without much movement, a handful of new treatments for this rare autoimmune disease are now approved, and ...

A depleter of pathogenic T cells, rosnilimab’s novel MOA generated a differentiated efficacy, tolerability and safety profile in recent Phase 2b study ...

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer drug Keytruda.

The settlement agreement will extend market exclusivity for AbbVie's JAK inhibitor in the U.S. until 2037—providing pediatric ...

LB Pharma has finally done it. The biotech IPO stalemate has been broken, with the neuroscience-focused company landing on ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

President Donald Trump is considering tariff exemptions for certain “non-patented” pharmaceuticals, though the White House ...

Ivonescimab elicited better overall survival in Asian patients with non-small cell lung cancer than in those from North ...

While a win for consumers, the regulatory action did nothing to stem the manufacture of compounded versions of the popular ...

Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...